Mylan Pharmaceuticals has reached a definitive resolution in its antitrust case, agreeing to a $73.5 million settlement with a group of direct EpiPen buyers. This settlement received final approval from a federal judge in Kansas, concluding accusations against Mylan and Pfizer. The plaintiffs claimed these companies collaborated to delay the introduction of a generic EpiPen, which allegedly resulted in inflated prices for the emergency medical device.
The lawsuit was initiated by institutional drug resellers who argued that Mylan, along with Pfizer, engaged in actions that stymied competition in the marketplace. By purportedly hindering the entry of generic alternatives, the companies were accused of maintaining an artificially high price tag on EpiPens, an essential treatment for severe allergic reactions.
Details of the settlement can be reviewed in the original article on Law360, which covers the implications of the litigation and the broader impact on pharmaceutical market practices.